At EverExcel, we believe that life sciences currently represents one of the most compelling investment themes in the United States.
The recent success of Luma Group’s portfolio company, Vaccine Company (VaxCo), which entered into an agreement to be acquired by Eli Lilly and Company for up to $1.55 billion, is another reminder of the extraordinary innovation taking place across the U.S. life sciences ecosystem.
Luma Group was a co-founding investor in VaxCo, backing the company at its earliest stages as it developed a next-generation vaccine platform.
Advances in biotechnology, artificial intelligence, genomics, and precision medicine are accelerating the pace of discovery and creating opportunities to address some of the world’s most significant healthcare challenges.
Our investment in the Luma Group reflects our conviction that exceptional returns are often generated by backing outstanding teams working on transformative technologies before they become obvious to the broader market.
The Vaccine Company outcome demonstrates the value that can be created when breakthrough science is combined with strong execution, and a long-term vision.
Congratulations to the entire Luma Group, Vaccine Company and Eli Lilly and Company teams on this remarkable achievement.